As of 2026-03-27, the EV/EBITDA ratio of Anika Therapeutics Inc (ANIK) is -31.26. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Anika's latest enterprise value is 155.21 mil USD. Anika's TTM EBITDA according to its financial statements is -4.96 mil USD. Dividing these 2 quantities gives us the above Anika EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.6x - 14.7x | 12.0x |
| Forward P/E multiples | 12.6x - 16.6x | 15.6x |
| Fair Price | (0.34) - (1.07) | (0.77) |
| Upside | -102.3% - -107.2% | -105.2% |
| Date | EV/EBITDA |
| 2026-03-25 | -30.71 |
| 2026-03-24 | -29.90 |
| 2026-03-23 | -29.87 |
| 2026-03-20 | -28.65 |
| 2026-03-19 | -29.61 |
| 2026-03-18 | -29.40 |
| 2026-03-17 | -30.56 |
| 2026-03-16 | -30.13 |
| 2026-03-13 | -29.66 |
| 2026-03-12 | -29.95 |
| 2026-03-11 | -30.13 |
| 2026-03-10 | -30.42 |
| 2026-03-09 | -31.87 |
| 2026-03-06 | -29.43 |
| 2026-03-05 | -29.81 |
| 2026-03-04 | -30.13 |
| 2026-03-03 | -30.25 |
| 2026-03-02 | -30.01 |
| 2026-02-27 | -30.13 |
| 2026-02-26 | -25.57 |
| 2026-02-25 | -20.20 |
| 2026-02-24 | -19.93 |
| 2026-02-23 | -20.14 |
| 2026-02-20 | -19.30 |
| 2026-02-19 | -19.50 |
| 2026-02-18 | -18.98 |
| 2026-02-17 | -18.69 |
| 2026-02-13 | -18.08 |
| 2026-02-12 | -17.64 |
| 2026-02-11 | -18.19 |
| 2026-02-10 | -18.42 |
| 2026-02-09 | -18.13 |
| 2026-02-06 | -18.80 |
| 2026-02-05 | -18.34 |
| 2026-02-04 | -19.41 |
| 2026-02-03 | -17.52 |
| 2026-02-02 | -16.39 |
| 2026-01-30 | -15.23 |
| 2026-01-29 | -15.00 |
| 2026-01-28 | -14.94 |
| 2026-01-27 | -15.00 |
| 2026-01-26 | -15.23 |
| 2026-01-23 | -15.46 |
| 2026-01-22 | -15.69 |
| 2026-01-21 | -16.07 |
| 2026-01-20 | -15.90 |
| 2026-01-16 | -15.46 |
| 2026-01-15 | -16.10 |
| 2026-01-14 | -16.13 |
| 2026-01-13 | -16.16 |